United States · 
Who invested in Nexo Therapeutics?
Nexo Therapeutics's investors include New Enterprise Associates, Versant Ventures and Cormorant Asset Management.
202420252026
$60MSeries A$60MRound
United States · Series A startup
Who invested in Nexo Therapeutics
Funding summaryUpdated 26 Oct 2026
$120Mraised across 2 rounds since 2023, from 2 sources
$60MSeries A$60MRound
- Latest round
- Round, $60MMar 2026
- Investors
- 3
The funding story
Each circle is a round, placed by date and sized by amount. The line above is the running total.
- First round
- Series A, $60M Jul 2023
- Biggest round
- $60M Round · Mar 2026
- Between rounds
- 2.8 years from the last two
The rounds
- Mar 2026Round$60M
No investor was named in the report.
Filed with the SEC (Form D); no report of this raise yetSEC filing: $60M sold, first sale Mar 2026
- Jul 2023
Founders and team
From Nexo Therapeutics's own website: 3 on the team.
Who was in which round
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Everyone who backed them
Missing a round, or an investor who was in one? Tell us.
Quick answers about Nexo Therapeutics
How much has Nexo Therapeutics raised?
Nexo Therapeutics has raised $120M across 2 rounds since 2023.
When did Nexo Therapeutics last raise?
Nexo Therapeutics's most recent round, $60M, was in Mar 2026.
What was Nexo Therapeutics's biggest round?
Its most recent round, $60M in Mar 2026, is also its largest on record.
Who backed Nexo Therapeutics first?
Nexo Therapeutics's first round on record, in Jul 2023, was backed by New Enterprise Associates, Versant Ventures and Cormorant Asset Management.
What stage is Nexo Therapeutics at?
Nexo Therapeutics's latest named round is a Series A, in Jul 2023.
Where is Nexo Therapeutics based?
Nexo Therapeutics is based in the United States.
Companies like Nexo Therapeutics
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.